Abstract
Background: Cell free circulating DNA (cfcDNA) is a promising diagnostic tool for prostate cancer (PCa). This study aimed to measure the cfcDNA concentration and integrity in PCa patients using quantitative polymerase chain reaction (qPCR) analysis. This study also assessed the correlation between these molecular biomarkers with total prostate-specific antigen (PSA), Gleason score, prostate volume, and age. Methods: Eleven PCa patients and 9 persons with benign prostatic hyperplasia (BPH) were recruited. Blood samples were collected before prostate biopsy and plasma quantified by qPCR amplification of the ALU 115 DNA sequence, with the ratio of ALU 247 to ALU 115 reflecting cfcDNA integrity. Results: There were no significant differences in median, interquartile range (IQR) cfcDNA concentration or cfcDNA integrity between the patients with PCa (47.9 (214.93) ng/mL; 0.61 (0.49)) and persons with BPH (41.5 (55.13) ng/mL, p = 0.382; 0.67 (0.45), p = 0.342). A weakly positive correlation exists between cfcDNA concentration and total PSA (r = 0.200, p = 0.555) but not with age or Gleason score in PCa patients. Conclusion: cfcDNA concentration was relatively nonsignificantly higher in PCa patients in comparison to persons with BPH, whereas cfcDNA integrity was similar in both groups. Though limited in sample size, this study shows that cfcDNA concentration may be a potentially valuable noninvasive biomarker for the diagnosis of PCa.
Highlights
In the diagnosis and monitoring of prostate cancer (PCa), the most notable biomarker is prostate-specific antigen (PSA)
Blood samples were collected from consenting participants who were suspected of having PCa for the measurement of Cell free circulating DNA (cfcDNA) concentrations, cfcDNA integrity, and total prostate-specific antigen
(20/29, 69%) of these patients completed their biopsy for histological confirmation for prostate cancer (PCa); the remaining patients’ results (9/29, 31%) were not available (NA)
Summary
In the diagnosis and monitoring of prostate cancer (PCa), the most notable biomarker is prostate-specific antigen (PSA). Diseases 2020, 8, 34 diagnosis and monitoring of patients with PCa. Diseases 2020, 8, 34 diagnosis and monitoring of patients with PCa This is primarily due to the fact that PSA levels can increase in other prostatic diseases, such as prostatitis and benign prostatic hyperplasia (BPH) [3]. Cell free circulating DNA (cfcDNA) is a promising diagnostic tool for prostate cancer (PCa). This study assessed the correlation between these molecular biomarkers with total prostate-specific antigen (PSA), Gleason score, prostate volume, and age. Blood samples were collected before prostate biopsy and plasma quantified by qPCR amplification of the ALU 115 DNA sequence, with the ratio of ALU 247 to ALU 115 reflecting cfcDNA integrity. Results: There were no significant differences in median, interquartile range (IQR)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
